After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full heterogeneity of the disease.
After decades of hard-won progress, ALS drug development is entering a new era, building on established efficacy measures like survival and ALSFRS-R with biology-driven science that captures the full heterogeneity of the disease.
